



**FOR IMMEDIATE RELEASE: Calgary, Alberta – December 23, 2005**

**Vacci-Test™ signs Exclusive Global Distribution Agreement with QUELAB**

Vacci-Test™ Corporation (“VTC”) today announced that it has signed an agreement with Montreal, Quebec based Quclab Laboratories Inc. (“QUELAB”) to distribute on a world-wide basis QUELAB’s proprietary kit for the screening of **Actinobacillus Pleuropneumoniae** (“App”), a serious respiratory infection found in swine. App has 12 main serotypes in swine sera, which currently makes detection costly and time consuming due to individual testing of several different serotypes at a time. Vacci-Test™ App is an economical and rapid test that detects all 12 serotypes at once.

“The signing of this Agreement with QUELAB is a major step in VTC’s drive to commercialization using innovative, precise and economical diagnostic screening tests for infectious diseases in both humans and animals,” said William J. Hogan, President and CEO of VTC. “We believe that with QUELAB’s high caliber GMP manufacturing facilities and its development of a very unique and breakthrough product will allow VTC to provide an invaluable diagnostic tool to swine producers globally.”

“The signing of this Exclusive Distribution Agreement with VTC is the beginning of a long term business relation which will put VTC diagnostic kits on the international veterinary market,” said Roger Boulais, President of QUELAB. “The industry concerned with the detection and identification of microorganisms and diagnostics in general is in the fast lane for growth and represents an extraordinarily promising market.”

“Through MAXIVET Inc. (VTC’s Canadian arm of R&D and product validation), VTC will proceed to the validation (determination of sensitivity and specificity) of this App kit in order to confirm its commercial value”, said Dr. Maurice Bessette, President of MAXIVET. “In Canada , the potential App market is estimated at 150,000 tests annually. In Europe and the USA , the prospective market is 10 times higher. This gives VTC excellent and profitable commercial opportunities.”

**QUELAB** is a microbiological products manufacturer with a broad line of culture media, animal blood products and diagnostic kits. QUELAB places particular emphasis on the development and production of microbiological innovative tools for clinical and veterinary diagnostic centres; universities and research facilities; biotech and environmental laboratories; and quality control for the pharmaceutical and food industry.

**MAXIVET**, located in Saint-Hyacinthe, Quebec offers diagnostic services as well as the development and validation of diagnostic kits. MAXIVET also specializes in the detection of pathogens for agri-food and veterinary purposes.

**VTC** develops and markets innovative diagnostic screening kits for the presence of infectious diseases as well as the measurement of immunity protection in both humans and animals. The patented Vacci-Test™ series of products will allow for the rapid detection of infectious diseases and/or the precise evaluation of immune level status through a simple blood test. VTC will introduce several validated Vacci-Test™ products in 2006 including a non-laboratory lateral flow strip test, which provides veterinarians and practitioners with the in-field ability to detect Transmissible Spongiform Encephalopathies (“TSE”) brain infections using an independently discovered marker in the blood. Vacci-Test™ will specifically detect **BSE** in cattle and **new variant Creutzfeldt-Jakob Disease** in humans.”

For more information contact: William J. Hogan or The Honourable Charlie Mayer or visit [www.vacci-test.com](http://www.vacci-test.com) .

**Vacci-Test™ Corporation**

Suite 340 , 550 - 11th Avenue S.W.

Calgary , Alberta, Canada T2R 1M7

Bus: (403) 269-9424

Fax: (403) 263-6357

Canada Toll Free: 1-877-298-0208